Medtech Funding: How FDA Timelines Shape Every Round

In most startups, the next funding round is driven by revenue growth. In medical devices, it is driven by the regulator. A medtech company cannot sell in the United States until the Food and Drug Administration has cleared or approved its device, and the path it takes to get there determines how much capital it needs, how long it will take, and what investors will pay at each stage.

This guide explains the main FDA pathways, how funding rounds map onto regulatory milestones, and how founders and investors should plan around them.

1. The FDA Device Pathways

The FDA classifies devices by risk, and the class largely determines the pathway.

• Class I (low risk). Many are exempt from premarket review, allowing faster entry to market.
• Class II (moderate risk). Most go through a 510(k), showing the device is substantially equivalent to one already on the market. The FDA's review goal for a 510(k) is 90 FDA review days, though total time is often longer once questions and pauses are included.
• De Novo. For novel low-to-moderate risk devices with no suitable predicate, creating a new classification that later devices can reference.
• Class III (high risk). Usually require Premarket Approval (PMA), which typically needs clinical trial evidence of safety and effectiveness and takes significantly longer and costs more.

Devices that address serious conditions and offer meaningful advantages may qualify for the Breakthrough Devices Program, which provides more interaction with the FDA and prioritised review.

2. How Rounds Map to Milestones

• Pre-seed and seed: prototype, early bench testing, regulatory strategy and a clear view of the pathway.
• Series A: design freeze, verification and validation testing, quality system in place, and preparation for submission or clinical studies.
• Series B: clinical data (if required), regulatory submission and, ideally, clearance or approval.
• Growth rounds: commercial launch, reimbursement, sales team build-out and scale manufacturing.

Each milestone reduces risk and is the main driver of valuation step-ups. Raising too little to reach the next milestone is one of the most common and costly mistakes in medtech.

3. Clearance Is Not the Finish Line

FDA clearance lets you sell; it does not guarantee anyone will pay. Reimbursement from Medicare and private insurers often determines commercial success, and securing coding, coverage and payment can take as long as regulatory approval. Investors increasingly ask for a reimbursement strategy alongside the regulatory plan.

4. What Investors Diligence

• Regulatory strategy. Is the pathway realistic, and has the company engaged with the FDA, for example through pre-submission meetings?
• Predicate devices for a 510(k), and the risk that the FDA disagrees.
• Clinical plan and cost, including any investigational device exemption needed for studies.
• Quality system and manufacturing readiness.
• Reimbursement and adoption, including who pays and how clinicians will use the device.
• Capital to milestone. Does this round fund the company to the next de-risking event?

5. Funding Sources Beyond Venture

• Non-dilutive grants, such as SBIR and STTR programmes. See our guide to SBIR and STTR grants.
• Strategic investors from large medtech companies, who may also become acquirers.
• Venture debt after key milestones, to extend runway. See venture debt explained.

6. Exits

Most medtech exits are acquisitions by large device companies, often after regulatory clearance and early commercial traction, when much of the risk has been removed. Some companies list publicly, but acquisition remains the most common path. See our guide to exit strategies.

Frequently Asked Questions

How long does FDA clearance take?

It depends on the pathway. A 510(k) is usually months, while a PMA with clinical trials can take years. Planning and early FDA engagement shorten surprises.

Should we raise before or after FDA clearance?

Both, usually. Rounds before clearance fund the regulatory work; clearance itself is a major valuation step-up for the next round.

Is reimbursement really as important as FDA clearance?

Often yes. Without reimbursement, many hospitals and clinicians cannot adopt a device at scale.

Who invests in medtech startups?

Specialist healthcare venture funds, strategic investors from large device companies, angels with clinical backgrounds and government grant programmes.

The Bottom Line

In medtech, the regulatory pathway is the business plan. Founders who choose the right pathway, engage the FDA early, plan reimbursement in parallel and raise enough to reach each milestone give investors the clarity they need. Investors who map every round to a regulatory milestone can underwrite with far more confidence.

Global Capital Network connects medtech and life sciences founders with investors through our events and investor network. Get in touch if you are raising.

This article is general information, not regulatory or investment advice. FDA requirements and timelines vary by device; consult regulatory experts.